Table 1.
Added QALYs over baseline | Value of additional QALYS (in $B) | Costs (in $B) | Net monetary benefit ($B) | Incremental net monetary benefit ($B) | |
---|---|---|---|---|---|
Pre-CATIE | 265,000 | 26.5 | 6.7 | 19.80 | |
Partial coverage | 254,000 | 25.4 | 5.9 | 19.30 | −0.50 (vs pre-CATIE) |
No coverage | 251,000 | 25.1 | 5.4 | 19.70 | 0.40 (vs partial) |
Notes: Partial coverage implies access only to first generation perphenazine or second generation risperidone. No coverage implies access only to first generation perphenazine. Net monetary benefits = Value of QALYs ($B) − Costs ($B).